Wednesday, June 10, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

BASF’s 61-Euro Target: Wall Street Sees a Goldilocks Moment as Shareholders Weigh a Spin-Off

SiterGedge by SiterGedge
April 25, 2026
in Analysis, Chemicals, DAX
0
BASF Stock
0
SHARES
23
VIEWS
Share on FacebookShare on Twitter

The Ludwigshafen-based chemical giant is approaching a pivotal juncture that could reshape both its portfolio and its share price. With the stock trading at 54.32 euros—just shy of its 52-week high of 54.70 euros—analysts at Citigroup have raised their price target to 61 euros, maintaining a “Buy” rating. The call is built on what analyst Sebastian Satz describes as a “Goldilocks scenario,” where supply-side distortions across chemical value chains are expected to bolster BASF’s pricing power and margins in a way the market has yet to fully price in.

The optimism isn’t confined to one bank. Bernstein Research has also set a 61-euro target, pointing to significant upside versus the current consensus. Both houses see the second quarter of 2026 as the inflection point for earnings growth, and Citigroup has placed the stock on its “positive Catalyst Watch” list. The bullish thesis is reinforced by the company’s ongoing share buyback program, which has accumulated more than 19.5 million shares since its launch in November 2025. A fresh tranche of roughly 124,000 shares was repurchased in mid-April alone, tightening the supply of stock and providing a floor under the price.

For income-focused investors, BASF offers a dividend yield of 4.2 percent—one of the highest in the DAX this season. The proposed payout of 2.25 euros per share for fiscal 2025 matches the previous year’s level, which itself was a painful cut from 3.40 euros in 2024. Crucially, management has committed to a floor of at least 2.25 euros annually through 2028, providing a measure of predictability for those building a retirement portfolio. The annual general meeting on April 30 in Mannheim is expected to approve the dividend proposal.

That same meeting carries a far more consequential item on the agenda: shareholders will vote on whether to spin off the Agricultural Solutions division into a standalone subsidiary. The move is widely seen as a precursor to a potential initial public offering in Frankfurt next year. If approved, it would mark the most significant structural change since the company’s post-war reorganization. The agricultural unit, which develops crop protection products and seeds, has been a steady performer but operates with different cyclical dynamics than BASF’s core chemicals business.

Should investors sell immediately? Or is it worth buying BASF?

The operational backdrop remains challenging. CEO Markus Kamieth has described 2026 as “another transition year,” with EBITDA before special items expected to land between 6.2 billion and 7.0 billion euros. The cost-cutting program, however, is running ahead of schedule: annual savings are on track to reach 2.3 billion euros by the end of next year. The new Verbund site in Zhanjiang, China—the company’s seventh such integrated facility and its largest single investment ever at roughly 8.7 billion euros—began operations in late March. The plant runs entirely on renewable electricity and is central to BASF’s strategy of expanding in Asia while decarbonizing its production base.

The stock has rallied more than 21 percent since the start of the year, reflecting growing confidence in the turnaround. A sustained break above the 54.70-euro resistance level could end the sideways trading pattern that has characterized recent months. The next hard data point comes on Thursday, April 30, when BASF releases detailed first-quarter results alongside the shareholder meeting. Analysts are forecasting full-year earnings of 2.54 euros per share, making a strong Q1 report essential to validate the elevated expectations and the 61-euro price target.

For private investors assembling a dividend-based retirement strategy, BASF occupies a distinct niche: high current yield with a guaranteed floor, exposure to the cyclical chemicals sector, and a potential catalyst from the agricultural spin-off. It is a bet on structural transformation—one that requires patience but offers a safety net in the form of that locked-in dividend. Whether the market’s newfound optimism proves justified will become clearer after April 30, when the numbers and the vote are both in.

Ad

BASF Stock: Buy or Sell?! New BASF Analysis from June 10 delivers the answer:

The latest BASF figures speak for themselves: Urgent action needed for BASF investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from June 10.

BASF: Buy or sell? Read more here...

Tags: BASF
SiterGedge

SiterGedge

Related Posts

Plug Power Stock
Analysis

When a Helicopter Shot Down a Hydrogen Stock: Plug Power’s AGM Showdown Arrives Amid a 28% Rout

June 10, 2026
FALLBACK Stock
Chemicals

Germany Adds Pesticide-Triggered Parkinson’s to Occupational Disease List, as Only 30% of Claims Win Approval

June 10, 2026
Bayer Stock
Analysis

Bayer’s Slow Build: Clinical Evidence and Margin Pressures Define the Next Chapter

June 9, 2026
Next Post
Bayer Stock

Bayer’s High-Stakes Summer: A $7.25 Billion Settlement and a Pivotal Supreme Court Hearing

D-Wave Quantum Stock

D-Wave Quantum’s Rally Fades as Share Overhang and Insider Sales Trigger a 9% Wipeout

Voestalpine Stock

Voestalpine’s Deeply Oversold Stock Masks a Half-Billion Euro Rail Bonanza

Recommended

DrugRetailers Stock Bull Market

Analyst Projections and Future Growth Predictions for Kroger

2 years ago
Airbnb Stock

Airbnb Faces Dual Challenges as Insiders Sell and Fee Structure Shifts

9 months ago
Inspire Medical Stock

Institutional Confidence Grows for Inspire Medical Amid Mixed Analyst Sentiment

10 months ago
Finance_Fiscal (2)

Earnings Forecast and Stock Performance for Ovintiv

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Netflix Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Take-Two Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics XRP
No Result
View All Result

Highlights

AMD’s 12-Gigawatt AI Contract Haul Masks a 16% Pullback as Execution Hurdles Mount

Redwood AI’s Cash Burn and Uncommitted Quantum Deal Test Investor Patience

When a Helicopter Shot Down a Hydrogen Stock: Plug Power’s AGM Showdown Arrives Amid a 28% Rout

Hensoldt’s New German Fighter Coalition and Record Orders Fail to Sway Cautious Analysts

Jensen Huang’s Senate No-Show and the Quiet March of Nvidia’s AI Empire

Germany Adds Pesticide-Triggered Parkinson’s to Occupational Disease List, as Only 30% of Claims Win Approval

Trending

Uranium Energy Stock
Commodities

Uranium Energy’s Costly Wyoming Ramp Overshadows $794M Cash Pile and Zero-Revenue Strategy

by Kennethcix
June 10, 2026
0

Uranium Energy’s decision to hoard its uranium inventory rather than book a single dollar of revenue has...

Scottish Mortgage Investment Stock

Liquidity Drain From SpaceX IPO Compounds Scottish Mortgage’s Macro Headaches

June 10, 2026
CrowdStrike Stock

Software Resilience: The Defensive Trade as Inflation Bites and Hardware Stumbles

June 10, 2026
AMD Stock

AMD’s 12-Gigawatt AI Contract Haul Masks a 16% Pullback as Execution Hurdles Mount

June 10, 2026
Redwood AI Stock

Redwood AI’s Cash Burn and Uncommitted Quantum Deal Test Investor Patience

June 10, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Uranium Energy’s Costly Wyoming Ramp Overshadows $794M Cash Pile and Zero-Revenue Strategy
  • Liquidity Drain From SpaceX IPO Compounds Scottish Mortgage’s Macro Headaches
  • Software Resilience: The Defensive Trade as Inflation Bites and Hardware Stumbles

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com